Product Description
Belizatinib, also known as TSR-011, is an orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. (Sourced from: https://drugs.ncats.io/drug/Z8A6022P3J)
Mechanisms of Action: RTK Inhibitor, ALK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tesaro, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2013-000686-37 |
2013-000686-37 | P2 |
Completed |
Lymphoma |
2018-06-06 |
2022-03-13 |
Treatments |
|
NCT02048488 |
PR-20-5006-C | P2 |
Completed |
Lymphoma |
2016-09-01 |
2019-03-27 |
Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/09/2023 |
News Article |
ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development |
|
08/10/2021 |
News Article |
Anaplastic Lymphoma Kinase ALK Inhibitors Market, 2026 |
|
04/22/2021 |
News Article |
Worldwide Anaplastic Lymphoma Kinase ALK Inhibitors Industry to 2026 - Featuring Astellas Pharma, AstraZeneca ad Pfizer Among Others |
|
04/21/2021 |
News Article |
Insights on the Anaplastic Lymphoma Kinase ALK Inhibitors Global Market to 2026 - Lorbrena Overcomes Xalkori as Front-Line Therapy in NSCLC |